A subsequent study specifically evaluating FOXA2 reported an endometrioid adenocarcinoma mutation rate of 9.4%, with a spectrum of mutations again interpreted as consistent with a tumor suppressor role (22). The gene discussed is FOXA2; the disease is endometrioid adenocarcinoma.